Loading organizations...
Memorial Sloan Kettering Cancer Center delivers specialized cancer treatment, pioneering research, and comprehensive educational programs. It functions as a leading institution for understanding, preventing, and curing cancer. The center’s core offerings include advanced diagnostics, innovative therapies, and holistic patient care, integrating clinical practice with scientific discovery to improve outcomes.
Founded in 1884 as the New York Cancer Hospital, the institution originated from the vision of individuals like John Jacob Astor. This founding insight addressed the critical need for a facility solely focused on cancer care, distinct from general hospitals. This commitment established its path, leading to its current form as a global leader in oncology.
Cancer patients are the primary focus, seeking expert treatment across all disease stages. Memorial Sloan Kettering serves a broad population, providing comprehensive care from diagnosis through survivorship. Its vision is to conquer cancer as a major public health challenge, driven by rigorous scientific inquiry and compassionate, individualized treatment.
Key people at Memorial Sloan - Kettering Cancer Center.
Key people at Memorial Sloan - Kettering Cancer Center.
Memorial Sloan Kettering Cancer Center (MSKCC) is not a company but rather a leading nonprofit medical institution dedicated to cancer care, research, and education.[1][2] It operates as a research and treatment center, not a for-profit business entity.
MSKCC is one of the world's premier cancer research and treatment institutions, combining clinical oncology services with fundamental scientific research.[1] The organization's mission centers on advancing cancer care through integrated patient treatment, groundbreaking research, and education of the next generation of cancer researchers and physicians.[3] Rather than pursuing commercial investment returns, MSKCC operates as a nonprofit dedicated to cancer prevention, treatment innovation, and understanding the biology of malignant disease. The institution serves patients across multiple cancer specialties while maintaining a robust research enterprise that has contributed significantly to the development of chemotherapy drugs and immunotherapy approaches.[3][5]
MSKCC's history spans over 140 years, beginning in 1884 when physician J. Marion Sims advocated for a dedicated cancer hospital after being prevented from admitting cancer patients to other facilities.[1] Philanthropists funded the New York Cancer Hospital, which opened in Manhattan in 1887.[1] The institution evolved through major philanthropic support: in 1936, John D. Rockefeller Jr. donated land for a new Memorial Hospital location, and in 1945, Alfred P. Sloan Jr. (Chairman of General Motors) and Charles F. Kettering (Director of Research at GM) established the Sloan-Kettering Institute for Cancer Research with a $4 million gift.[1][3][4] The institute officially opened in 1948 and initially focused on discovering cancer-killing chemicals, yielding some of the first approved chemotherapy drugs.[3] The two institutions formally merged in 1980 to create the unified Memorial Sloan Kettering Cancer Center.[2][3]
MSKCC represents a model of philanthropically-funded medical research and care integration that has shaped modern oncology.[5] The institution's success in pediatric oncology during the 1960s—when the field began achieving meaningful treatment successes—demonstrated how dedicated cancer centers could drive practice-changing innovations.[2] As a nonprofit research institution, MSKCC operates outside the commercial venture capital ecosystem, instead relying on philanthropic support and patient care revenue to fund its mission. The center's influence extends globally, with additional facilities in India, and its research contributions have fundamentally advanced understanding of cancer biology and treatment approaches.[1]
